Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients

Table 2 P-values for univariate analysis of prognostic factors

	OS	EFS
Gender	0.081	0.211
Age (median)	0.828	0.770
Paraprotein subtype	0.382	0.393
ISS	0.026	0.645
VAD chemosensitivity	0.887	0.974
VGPR after induction	0.722	0.406
VGPR after auto-HSCT	0.181	0.357
Oligoclonal reconstitution	0.170	0.039
DAPK methylation	0.029	0.136

DS: Durie-Salmon stage; ISS: International staging system; VGPR: >90% reduction in paraprotein level; OS: overall survival; EFS: event-free survival

ISSN: 1479-5876